Idorsia’s Jean-Paul Clozel retires as CEO, plots next steps; CRISPR Therapeutics nabs CMO from Sanofi
→ Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
